Cabometyx 40 MG tablet 30S
Ended Awarded
- Contract number
- SPE2DR26FCFK9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $45,891
Award facts
- Contract value 100% obligated
- $45,890.94 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $45,890.94 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Cabometyx 40 mg tablets (30-count units). This delivery order, issued on November 20, 2025, with an ultimate completion date of November 21, 2025, carries no set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to ensure consistent pharmaceutical supply to military healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, positioning it to fulfill diverse and specialized pharmaceutical requirements across Department of Defense healthcare operations. The underlying PPV-G GEN V contract, designated SPE2DR and awarded on November 13, 2025, provides a $499,999,999 ceiling with a completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods.
Quick answers
Who was awarded contract SPE2DR26FCFK9?
SPE2DR26FCFK9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FCFK9 worth?
The government has obligated $45,891 on SPE2DR26FCFK9.
Is contract SPE2DR26FCFK9 an order under another contract?
Yes. SPE2DR26FCFK9 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFK9 competed?
The extent of competition for SPE2DR26FCFK9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award